July 13, 2022
ASCO 2022 Lymphoma In-Depth BookmarkGeorge Lundberg, MD
Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.
December 2, 2019
FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis BookmarkGeorge Lundberg, MD
Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.
Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.